Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000
- 1 April 2002
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (7), 1838-1844
- https://doi.org/10.1200/jco.2002.07.166
Abstract
PURPOSE: We have simplified the treatment of gestational trophoblastic disease (GTD) in order to reduce the number of patients exposed to potentially carcinogenic chemotherapy. Patients who score 0 to 8 on the Charing Cross scoring system are classified as low-risk and receive methotrexate (MTX) and folinic acid (FA), whereas those who score higher than 8 are classified as high-risk and receive the etoposide, methotrexate, and dactinomycin (EMA)/cyclophosphamide and vincristine (CO) regimen. PATIENTS AND METHODS: Between 1992 and 2000, 485 women with GTD were commenced on MTX/FA at Charing Cross Hospital, London, United Kingdom. If patients developed MTX resistance or toxicity, treatment was altered according to the level of beta human chorionic gonadotropin (hCG). If serum hCG was ≤ 100 IU/L, patients received dactinomycin; if hCG was greater than 100 IU/L, patients received EMA/CO. RESULTS: The median duration of follow-up was 4.7 years. Overall survival was 100% and the relapse rate was 3.3% (16 of 485 patients). hCG values normalized in 324 (66.8%) of 485 patients with MTX alone, whereas 161 (33.2%) of 485 patients required a change in treatment, 11 because of MTX toxicity and 150 because of MTX resistance. Sixty-seven patients changed to dactinomycin, of whom 58 achieved normal hCG values, and nine required third-line chemotherapy with EMA/CO. hCG values normalized in 93 (98.9%) of 94 patients who changed directly to EMA/CO from MTX. CONCLUSION: Single-agent dactinomycin has activity in patients with low-risk GTD who develop MTX resistance and whose hCG is low. Simplifying the stratification of GTD into two classes (low- and high-risk) does not compromise overall outcome and may reduce the risk of second tumors.Keywords
This publication has 18 references indexed in Scilit:
- Adjuvant hysterectomy in low-risk gestational trophoblastic diseasePublished by Ovid Technologies (Wolters Kluwer Health) ,2001
- Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer SocietyInternational Journal of Gynecologic Cancer, 2000
- Comparison of Chemotherapies with Methotrexate, VP-16 and Actinomycin-D in Low-Risk Gestational Trophoblastic DiseaseGynecologic and Obstetric Investigation, 1998
- 5-Day Methotrexate for Women with Metastatic Gestational Trophoblastic DiseaseGynecologic Oncology, 1994
- Correlation between clinical staging (FIGO) and prognostic groups with gestational trophoblastic diseaseBJOG: An International Journal of Obstetrics and Gynaecology, 1993
- Metastatic gestational trophoblastic disease: A comparison of prognostic classification systemsGynecologic Oncology, 1992
- Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989BJOG: An International Journal of Obstetrics and Gynaecology, 1991
- The role of low‐dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT)BJOG: An International Journal of Obstetrics and Gynaecology, 1989
- Metastatic gestational trophoblastic disease: Experience at the New England trophoblastic disease center from 1965 to 1985Gynecologic Oncology, 1987
- Developments in chemotherapy for medium‐ and high‐risk patients with gestational trophoblastic tumours (1979–1984)BJOG: An International Journal of Obstetrics and Gynaecology, 1986